Delineate

Name: Delineate
Brand: Delineate
Rating: 0 (1 reviews)

Delineate is an AI-driven research operations and analytics platform that converts unstructured scientific and clinical evidence into structured, analysis-ready datasets, automates literature search and triage, and extracts quantitative values from text, tables, and figures for model-informed drug development workflows.

1 Ref Customers

Website|FTEs 48

Published Oct 6, 2026

01Common complaints

(Required) Consider alternatives or delay purchase when: 1. A mature product with broad third-party reviews and widely documented certifications (for example, many G2/Gartner reviews and public SOC 2/ISO documentation) is required before procurement. 2. The primary need is literature search breadth rather than automated extraction and structuring; products such as Embase may be more suitable. 3. Workflows demand fully validated, regulator-ready traceability out of the box and internal teams cannot allocate resources for additional validation. 4. Budget constraints or small teams make hiring contractors or using existing tools more cost-effective for occasional systematic reviews. 5. The IT/security team requires SOC 2/ISO documentation prior to initiating an RFP; there is limited public evidence of such artifacts for delineate.pro.

Deal disqualifiers (poor fit)

Teams requiring a fully self-serve SaaS with publicly transparent pricing and extensive public compliance documentation.
Highly regulated environments that need validated, regulator-ready traceability and packaged certifications with minimal vendor due diligence effort.
Use cases where the corpus is small and manual extraction is already efficient.

Publicly acknowledged limitations

No explicit product limitations were documented on delineate.pro public sources. Publicly available material is limited.

Roadmap items

Not publicly documented.

Scale limitations

Not publicly documented; the vendor describes large-scale studies but does not provide detailed public metrics.

Security and compliance gaps

No public SOC 2 or ISO documentation for delineate.pro was found. This is a significant procurement consideration until vendor-provided documentation is available.

Ecosystem ambiguity and brand collision

The term “Delineate” refers to multiple companies and products across different domains (market research delineate.ai; ecommerce analytics delineate.co; and the biopharma delineate.pro). This can:
- Confuse procurement and reference checks.
- Pollute search results and increase due diligence overhead.

Sources: multiple LinkedIn pages and site references for different “Delineate” entities.

02Why they buy

Validated (partially) by available materials: - Focus on extracting quantitative information from figures and plots, which the vendor highlights as a capability. - Automated triage across PubMed and ClinicalTrials.gov described in vendor materials. - Vendor-reported claims of substantial throughput improvements for certain workflows (numerical multipliers and time reductions are reported by the vendor; methodology is not publicly disclosed). - A browser extension that facilitates capturing PDFs into projects during browsing. Counterbalance: established vendors may provide broader coverage, deeper integrations, and more public security/compliance documentation. Sources: YC launch page; BIO exhibitor listing; Chrome Web Store extension.

Sources: YC launch page; BIO exhibitor listing; Chrome Web Store extension.

Key Differentiator

03Field reports

Review-platform coverage (Gartner Peer Insights, G2, TrustRadius)

Gartner Peer Insights: no Delineate product page or reviews were found in accessible search results.
G2: no Delineate reviews were found in accessible search results.
TrustRadius: no Delineate reviews were found in accessible search results.

This limited visibility on public review platforms is common for early-stage, enterprise-sold biotech tools where customer feedback is often shared privately or embedded within vendor case studies.

Other review-like signals

Chrome Web Store (Delineate extension) - Rating: highly positive, based on a very small number of ratings (not representative of enterprise deployment). - Description: the extension identifies academic papers, locates open-access PDFs, and uploads them to projects. Source: Official browser extension listing. Community / Reddit - Search results surfaced community posts that appear unrelated to the biopharma product (discussions using the word “delineate” in other contexts). These are not reliable signals about the Delineate product. Source: Community discussion threads returned by search.

Reasons cited by the vendor for adoption (inferred from vendor materials)

To reduce time spent on manual evidence aggregation.
To extract quantitative values from plots and figures at greater scale than manual extraction.
To accelerate MBMA/MIDD workflows according to vendor statements.

Sources: Official vendor launch and company pages; industry exhibitor listings.

Reasons customers might discontinue use (inferred risk areas)

Because independent reviews are scarce, potential reasons for churn should be inferred from typical failure modes in this category:

Continued QC burden if extracted values lack transparent provenance.
Mismatch with regulated validation expectations or procurement requirements.
Cost of vendor services versus building internal capability.
IT/security procurement friction due to limited publicly documented certifications.

Vendor-published outcomes (not independently verified)

From vendor-published items and launch materials: - A vendor claim of a substantial increase in the number of processed studies versus an industry baseline. - A vendor claim of significantly shortened timelines for certain studies. - A vendor claim of partnerships with multiple large pharmaceutical companies (described as “top-tier” in some vendor materials). From LinkedIn: - A post references collaboration with a Sanofi team where Delineate supported processing a large volume of publications to create a human PK database; this reference to a named external company is a stronger signal than anonymized claims but should be validated. Critical evaluation: - These outcomes are plausible but have not been independently audited. - Metrics lack public definitions and benchmarking context (for example, what constitutes a “processed study,” baselines used, and QC thresholds). - Recommended buyer diligence: request redacted sample datasets with provenance metadata and QC logs for evaluation. Sources: Official vendor documentation; LinkedIn company page.

NIH STTR grant (signal, but not a product KPI)

A LinkedIn post by the CEO states Delineate received a small federal research grant in collaboration with an academic partner focused on accelerating QSP model development and repurposing.

Critical evaluation:

A grant is a validation signal for technical feasibility or research alignment but does not necessarily indicate enterprise readiness, product maturity, or performance in operational deployments.

Source: LinkedIn company/CEO post.

04Best fit

Company size

Most plausible ICP (inferred):

Mid-size biotechnology companies to large pharmaceutical firms.
Teams with dedicated clinical pharmacology, pharmacometrics, or evidence synthesis functions.
Organizations that repeatedly run systematic reviews or MBMA projects where onboarding costs can be amortized across multiple projects.

Industries / verticals

Biopharma, pharmaceutical R&D, and contract research organizations (CROs) that perform evidence synthesis and modeling.

Roles and personas

Decision makers: Head/VP of Clinical Pharmacology, Pharmacometrics leaders, Translational Medicine leads, R&D data/AI leadership.
End users: pharmacometricians, clinical scientists, evidence synthesis specialists, medical writers, and data scientists.

Qualification criteria (good fit)

Regular need for evidence aggregation across a substantial corpus of published literature.
High value associated with accelerating decision timelines (portfolio prioritization, trial design, endpoint selection).
Willingness to run a pilot and validate outputs against internal standards.

05The pitch

What the product does (core value proposition)

Delineate is described as an AI-driven research operations and analytics product/service aimed at biopharma and pharma R&D teams. The vendor states the product converts unstructured scientific and clinical evidence (papers, patents, and clinical-trial sources) into structured, analysis-ready datasets and positions this as an alternative to manual systematic review and data extraction. Based on vendor and third-party descriptions, Delineate’s capabilities typically include: - Evidence discovery / triage: automated searching and screening against inclusion criteria (e.g., PubMed and ClinicalTrials.gov). - Data extraction: extracting quantitative values from text and tables and using methods to extract data from plots and figures (e.g., PK/PD plots, Kaplan–Meier curves). - Quality control workflows: the vendor describes human-in-the-loop QC processes; limited technical details are publicly documented. - Workflow acceleration: the vendor reports reductions in time-to-dataset for MBMA/MIDD-style work. Sources: accelerator program/company launch materials; conference exhibitor listing; LinkedIn company profile; browser extension listing.

Target market and positioning

- Primary users: clinical pharmacology, pharmacometrics, translational medicine, and evidence synthesis teams at pharmaceutical and biotechnology companies. - Primary use cases: systematic reviews, model-based meta-analysis (MBMA), model-informed drug development (MIDD), and dataset creation to inform trial design decisions. - Positioning: the vendor describes the product using the term “agents” / “agentic systems” to indicate automation of search and triage workflows. Sources: accelerator program/company listing; conference exhibitor description; LinkedIn company page.

Get a comprehensive analysis of Delineate including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →

Published Oct 6, 2026

01Common complaints

(Required)

Consider alternatives or delay purchase when:

A mature product with broad third-party reviews and widely documented certifications (for example, many G2/Gartner reviews and public SOC 2/ISO documentation) is required before procurement.
The primary need is literature search breadth rather than automated extraction and structuring; products such as Embase may be more suitable.
Workflows demand fully validated, regulator-ready traceability out of the box and internal teams cannot allocate resources for additional validation.
Budget constraints or small teams make hiring contractors or using existing tools more cost-effective for occasional systematic reviews.
The IT/security team requires SOC 2/ISO documentation prior to initiating an RFP; there is limited public evidence of such artifacts for delineate.pro.

Deal disqualifiers (poor fit)

Teams requiring a fully self-serve SaaS with publicly transparent pricing and extensive public compliance documentation.
Highly regulated environments that need validated, regulator-ready traceability and packaged certifications with minimal vendor due diligence effort.
Use cases where the corpus is small and manual extraction is already efficient.

Publicly acknowledged limitations

No explicit product limitations were documented on delineate.pro public sources. Publicly available material is limited.

Roadmap items

Not publicly documented.

Scale limitations

Not publicly documented; the vendor describes large-scale studies but does not provide detailed public metrics.

Security and compliance gaps

No public SOC 2 or ISO documentation for delineate.pro was found. This is a significant procurement consideration until vendor-provided documentation is available.

Ecosystem ambiguity and brand collision

The term “Delineate” refers to multiple companies and products across different domains (market research delineate.ai; ecommerce analytics delineate.co; and the biopharma delineate.pro). This can:
- Confuse procurement and reference checks.
- Pollute search results and increase due diligence overhead.

Sources: multiple LinkedIn pages and site references for different “Delineate” entities.

02Why they buy

Validated (partially) by available materials:

Focus on extracting quantitative information from figures and plots, which the vendor highlights as a capability.
Automated triage across PubMed and ClinicalTrials.gov described in vendor materials.
Vendor-reported claims of substantial throughput improvements for certain workflows (numerical multipliers and time reductions are reported by the vendor; methodology is not publicly disclosed).
A browser extension that facilitates capturing PDFs into projects during browsing.

Counterbalance: established vendors may provide broader coverage, deeper integrations, and more public security/compliance documentation.

Sources: YC launch page; BIO exhibitor listing; Chrome Web Store extension.

Sources: YC launch page; BIO exhibitor listing; Chrome Web Store extension.

Key Differentiator

03Field reports

Review-platform coverage (Gartner Peer Insights, G2, TrustRadius)

Gartner Peer Insights: no Delineate product page or reviews were found in accessible search results.
G2: no Delineate reviews were found in accessible search results.
TrustRadius: no Delineate reviews were found in accessible search results.

This limited visibility on public review platforms is common for early-stage, enterprise-sold biotech tools where customer feedback is often shared privately or embedded within vendor case studies.

Other review-like signals

Chrome Web Store (Delineate extension)

Rating: highly positive, based on a very small number of ratings (not representative of enterprise deployment).
Description: the extension identifies academic papers, locates open-access PDFs, and uploads them to projects.

Source: Official browser extension listing.

Community / Reddit

Search results surfaced community posts that appear unrelated to the biopharma product (discussions using the word “delineate” in other contexts). These are not reliable signals about the Delineate product.

Source: Community discussion threads returned by search.

Reasons cited by the vendor for adoption (inferred from vendor materials)

To reduce time spent on manual evidence aggregation.
To extract quantitative values from plots and figures at greater scale than manual extraction.
To accelerate MBMA/MIDD workflows according to vendor statements.

Sources: Official vendor launch and company pages; industry exhibitor listings.

Reasons customers might discontinue use (inferred risk areas)

Because independent reviews are scarce, potential reasons for churn should be inferred from typical failure modes in this category:

Continued QC burden if extracted values lack transparent provenance.
Mismatch with regulated validation expectations or procurement requirements.
Cost of vendor services versus building internal capability.
IT/security procurement friction due to limited publicly documented certifications.

Vendor-published outcomes (not independently verified)

From vendor-published items and launch materials:

A vendor claim of a substantial increase in the number of processed studies versus an industry baseline.
A vendor claim of significantly shortened timelines for certain studies.
A vendor claim of partnerships with multiple large pharmaceutical companies (described as “top-tier” in some vendor materials).

From LinkedIn:

A post references collaboration with a Sanofi team where Delineate supported processing a large volume of publications to create a human PK database; this reference to a named external company is a stronger signal than anonymized claims but should be validated.

Critical evaluation:

These outcomes are plausible but have not been independently audited.
Metrics lack public definitions and benchmarking context (for example, what constitutes a “processed study,” baselines used, and QC thresholds).
Recommended buyer diligence: request redacted sample datasets with provenance metadata and QC logs for evaluation.

Sources: Official vendor documentation; LinkedIn company page.

NIH STTR grant (signal, but not a product KPI)

A LinkedIn post by the CEO states Delineate received a small federal research grant in collaboration with an academic partner focused on accelerating QSP model development and repurposing.

Critical evaluation:

A grant is a validation signal for technical feasibility or research alignment but does not necessarily indicate enterprise readiness, product maturity, or performance in operational deployments.

Source: LinkedIn company/CEO post.

04Best fit

Company size

Most plausible ICP (inferred):

Mid-size biotechnology companies to large pharmaceutical firms.
Teams with dedicated clinical pharmacology, pharmacometrics, or evidence synthesis functions.
Organizations that repeatedly run systematic reviews or MBMA projects where onboarding costs can be amortized across multiple projects.

Industries / verticals

Biopharma, pharmaceutical R&D, and contract research organizations (CROs) that perform evidence synthesis and modeling.

Roles and personas

Decision makers: Head/VP of Clinical Pharmacology, Pharmacometrics leaders, Translational Medicine leads, R&D data/AI leadership.
End users: pharmacometricians, clinical scientists, evidence synthesis specialists, medical writers, and data scientists.

Qualification criteria (good fit)

Regular need for evidence aggregation across a substantial corpus of published literature.
High value associated with accelerating decision timelines (portfolio prioritization, trial design, endpoint selection).
Willingness to run a pilot and validate outputs against internal standards.

05The pitch

What the product does (core value proposition)

Based on vendor and third-party descriptions, Delineate’s capabilities typically include:

Evidence discovery / triage: automated searching and screening against inclusion criteria (e.g., PubMed and ClinicalTrials.gov).
Data extraction: extracting quantitative values from text and tables and using methods to extract data from plots and figures (e.g., PK/PD plots, Kaplan–Meier curves).
Quality control workflows: the vendor describes human-in-the-loop QC processes; limited technical details are publicly documented.
Workflow acceleration: the vendor reports reductions in time-to-dataset for MBMA/MIDD-style work.

Sources: accelerator program/company launch materials; conference exhibitor listing; LinkedIn company profile; browser extension listing.

Target market and positioning

Primary users: clinical pharmacology, pharmacometrics, translational medicine, and evidence synthesis teams at pharmaceutical and biotechnology companies.
Primary use cases: systematic reviews, model-based meta-analysis (MBMA), model-informed drug development (MIDD), and dataset creation to inform trial design decisions.
Positioning: the vendor describes the product using the term “agents” / “agentic systems” to indicate automation of search and triage workflows.

Sources: accelerator program/company listing; conference exhibitor description; LinkedIn company page.

Get a comprehensive analysis of Delineate including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →